Doxorubicin
- PDF / 169,969 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 7 Downloads / 199 Views
1 S
Febrile neutropenia: case report A 43-year-old woman developed febrile neutropenia during treatment with doxorubicin for metastatic leiomyosarcoma. The woman presented to the general practitioner with left knee pain for few-months and noticed a left-sided supraclavicular fossa (SCF) mass. After evaluation, she was diagnosed with grade 2 metastatic leiomyosarcoma. Therefore, she underwent immediate prophylactic stabilisation of her left femur and radiotherapy. Several days later, she developed maculopapular erythematous rash on the upper chest and face in sun-exposed regions. No environmental, drug or infective triggers were detected. Thereafter, she started receiving first-line palliative chemotherapy with doxorubicin [dosage and route not stated]. She was treated with topical hydrocortisone and diprobase emollient cream. Her rash resolved with first cycle of systemic doxorubicin and topical steroidal treatment. She well-tolerated the chemotherapy, with exception of one episode of febrile neutropenia related to doxorubicin [duration of treatment to reaction onset not stated]. The woman’s doxorubicin dose was therefore reduced by 25%. She completed the scheduled six cycles of chemotherapy resulting in overall stable disease. Two months later, she presented with new-onset rash, proximal limb weakness and periorbital oedema. Detailed investigations confirmed the diagnosis of paraneoplastic dermatomyositis with leiomyosarcoma progression. She was treated with clobetasol and prednisolone with clinical improvement in paraneoplastic dermatomyositis. Thereafter, she received a second-line chemotherapy with trabectedin with further improvement in dermatologic symptoms [outcome of ADR not stated]. Merry E, et al. Paraneoplastic dermatomyositis associated with metastatic leiomyosarcoma of unknown primary. Clinical Sarcoma Research 10: 25 Aug 2020. Available from: URL: http://doi.org/10.1186/s13569-020-00140-w 803503737
0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 26 Sep 2020 No. 1823
Data Loading...
